Tracking recent β-thal and CALD gene therapy launches with bluebird’s CEO
Andrew Obenshain describes key metrics bluebird is seeing early in the launch of two of its gene therapies on its Q2 earnings day.
Also look for unique social pages for BiotechTV U.
#1. Pfizer’s CEO on Q2 earnings.
#2. Moderna CEO Stéphane Bancel on Moderna’s business at its R&D Day in New York
#3. UPenn’s Bruce Levine discusses the progress of CAR-T
#4. Learning about gene writing at Tessera Therapeutics
#5. Visiting Bayer’s Research and Innovation Center in Kendall Square